Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity.
Bhingarkar A, Wang Y, Hoshitsuki K, Eichinger KM, Rathod S, Zhu Y, Lyu H, McNutt AT, Moreland LW, McDermott L, Koes DR, Fernandez CA.
Bhingarkar A, et al. Among authors: zhu y.
Front Pharmacol. 2025 Jan 9;15:1397995. doi: 10.3389/fphar.2024.1397995. eCollection 2024.
Front Pharmacol. 2025.
PMID: 39850568
Free PMC article.